Cipla has announced the appointment of Mr Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), effective from 18th May 2026. This strategic appointment was approved during the company’s board meeting held on 13th May 2026.
Mr Kulkarni will also serve as a member of Cipla‘s Management Council and Senior Management Personnel. He brings a wealth of experience to the role, having previously held senior leadership positions at Dr Reddy’s Laboratories, Glenmark, and Zydus Lifesciences. His career spans over three decades, during which he has demonstrated a strong track record in scaling R&D operations and executing complex programmes in regulated markets.
Prior to joining Cipla, Mr Kulkarni was the Global Head – Integrated Product Development Organisation (IPDO) at Dr Reddy’s Laboratories. He has also worked with Torrent Research Centre, Sandoz India, and Rhone Poulenc (India) Limited. His expertise includes multiple filings and approvals across regulated and semi-regulated markets across diverse dosage forms.
Mr Kulkarni holds a Bachelor’s and Master’s degree in Pharmacy from Shivaji University and the University of Mumbai, respectively. Outside of his professional commitments, he has a keen interest in reading history, autobiographies, and spirituality. He is also passionate about fitness, writing, photography, and driving.
In addition to this appointment, the board meeting also approved the convening of Cipla’s 90th Annual General Meeting on 25th June 2026, the grant of stock options and employee stock appreciation rights under the Cipla Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021, and the appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).